Viridian Therapeutics Enters Material Definitive Agreement
Ticker: VRDN · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1590750
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Viridian Therapeutics signed a big deal on April 10th, details TBD.
AI Summary
Viridian Therapeutics, Inc. entered into a Material Definitive Agreement on April 10, 2024. The filing does not disclose the specific nature or terms of this agreement, only that it is material and definitive.
Why It Matters
This filing indicates a significant event for Viridian Therapeutics, potentially impacting its business operations, partnerships, or financial standing, though details are not yet public.
Risk Assessment
Risk Level: medium — The lack of specific details about the material definitive agreement introduces uncertainty and potential risk for investors.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- April 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36483 (filing_id) — SEC File Number
- 47-1187261 (tax_id) — IRS Employer Identification No.
- 221 Crescent Street, Suite 401 (address) — Business and Mail Address
- Waltham (city) — Business and Mail City
- MA (state) — Business and Mail State
- 02453 (zip_code) — Business and Mail ZIP
FAQ
What is the nature of the Material Definitive Agreement entered into by Viridian Therapeutics?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on April 10, 2024.
When was the Material Definitive Agreement reported to be entered into?
The earliest event reported, which is the entry into the Material Definitive Agreement, occurred on April 10, 2024.
What is Viridian Therapeutics, Inc.'s state of incorporation?
Viridian Therapeutics, Inc. is incorporated in Delaware.
What is the SEC File Number for Viridian Therapeutics, Inc.?
The SEC File Number for Viridian Therapeutics, Inc. is 001-36483.
Where is Viridian Therapeutics, Inc. located?
Viridian Therapeutics, Inc. is located at 221 Crescent Street, Suite 401, Waltham, MA 02453.
Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2024-04-16 16:06:04
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
- $38,232.33 — ompany during the Extended Term will be $38,232.33 per month for the first year of the Ext
- $104,270 — nt allowance in an amount not to exceed $104,270, (ii) a three-year extension option and
Filing Documents
- d769681d8k.htm (8-K) — 25KB
- g769681g0416091639962.jpg (GRAPHIC) — 3KB
- 0001193125-24-097728.txt ( ) — 152KB
- vrdn-20240410.xsd (EX-101.SCH) — 3KB
- vrdn-20240410_lab.xml (EX-101.LAB) — 18KB
- vrdn-20240410_pre.xml (EX-101.PRE) — 11KB
- d769681d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: April 16, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director